Portal de Periódicos da CAPES

A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

2023; Nature Portfolio; Volume: 13; Issue: 1 Linguagem: Inglês

10.1038/s41598-023-36990-9

2045-2322

Thomas Starkey, Maria C. Ionescu, Michaël Tilby, Martin Little, Emma Burke, Matthew W. Fittall, Sam Khan, Justin K. H. Liu, James R. Platt, Rosie Mew, Arvind Tripathy, Isabella Watts, Sophie Williams, Nathan Appanna, Youssra Al-Hajji, Matthew Barnard, Liza Benny, Alexander Burnett, Jola Bytyci, Emma Cattell, Vinton W.T. Cheng, James J. Clark, Leonie Eastlake, Kate Gerrand, Q. Ghafoor, Simon Grumett, Catherine Harper‐Wynne, Rachel E. Kahn, Alvin Lee, Oliver Lomas, Anna Lydon, Hayley McKenzie, Emma Kinloch, Emily Lam, Gillian Murphy, Malcolm Rhodes, Kate Robinson, Hari Panneerselvam, Jennifer Pascoe, Grisma Patel, Vijay Patel, Vanessa Potter, Amelia Randle, Anne Rigg, Tim Robinson, Rebecca Roylance, Tom Roques, Stefan Rozmanowski, René L. Roux, Ketan Shah, Remarez Sheehan, Martin Sintler, Sanskriti Swarup, Harriet Taylor, Tania Tillett, Mark Tuthill, Sarah Williams, Yuxin Ying, Andrew D. Beggs, Timothy Iveson, Siow Ming Lee, Gary Middleton, Mark R. Middleton, Andrew Protheroe, Tom Fowler, Peter Johnson, Lennard Y. W. Lee,

COVID-19 Clinical Research Studies

Abstract Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.